natgillin/translations-raw huggingface dataset:
• Infected lesions that exceed 10 cm in length or a total surface area >100 cm2. 
• Inficirane lezije koje duljinom prelaze 10 cm ili im je ukupna površina >100 cm2.
This non-target specific efflux mechanism has also been demonstrated to reduce the in vitro activity of streptogramin A. 
Za ovaj ciljno nespecifični mehanizam efluksa se također pokazalo da smanjuje in vitro aktivnost streptogramina A.
Altargo is for use on the skin only. 
Altargo se primjenjuje samo na koži.
The explanation for lower clinical efficacy against MRSA in SIOW is unclear and it may have been influenced by the presence of a particular MRSA clone. 
Objašnjenje za slabiju kliničku djelotvornost protiv MRSA kod SIORa je nejasno, a može biti povezano s prisutnošću određenog klona MRSA.
ITTC- Intent to Treat Clinical Primary Efficacy Population; PPC -Per Protocol Clinical Primary Efficacy population; ITTB- Intent to Treat Bacteriological evaluable, Primary Efficacy Population; PPB - Per Protocol Bacteriologically evaluable, Primary Efficacy Population. 
ITTC - Klinička populacija koja se namjerava liječiti, za procjenu primarne djelotvornosti (Intent to Treat Clinical Primary Efficacy Population); PPC - Klinička populacija za primarnu djelotvornost prema planu ispitivanja (Per Protocol Clinical Primary Efficacy population); ITTB - Bakteriološki ocjenjiva populacija koja se namjerava liječiti, za primarnu djelotvornost (Intent to Treat Bacteriological evaluable, Primary Efficacy Population); PPB - Bakteriološki ocjenjiva populacija za primarnu djelotvornost prema planu ispitivanja (Per Protocol Bacteriologically evaluable, Primary
However, in the two studies that enrolled patients with SIOW the efficacy of retapamulin in infections due to MRSA was inadequate (75.7%). 
Međutim, u dva ispitivanja koja su uključila ispitanike sa SIOR, djelotvornost retapamulina na infekcije izazvane MRSA-om nije bila zadovoljavajuća (75,7%).
After applying your ointment, you may cover the treated area with a sterile bandage or gauze dressing, unless your doctor has told you to leave it uncovered. 
Nakon primjene masti, tretirano područje možete pokriti sterilnim zavojem ili gazom, osim ako Vam liječnik nije rekao da ga ostavite nepokrivenog.
In studies in impetigo and in two studies of secondarily infected open wounds (SIOW), clinical success rates were high for retapamulin in patients with mupirocin-resistant S. aureus (100%: 11/11) or fusidic acid-resistant S. aureus (96.7%: 29/30). 
U ispitivanjima impetiga i u dva ispitivanja sekundarno inficiranih otvorenih rana (SIOR), klinički uspjeh terapije bio je visok za retapamulin u bolesnika sa S. aureus rezistentnim na mupirocin (100%: 11/11) ili S. aureus rezistentnim na fusidičku kiselinu (96,7%: 29/30).
If there is no improvement in your infection after two to three days of treatment contact your doctor. 
Vaše infekcije nakon dva do tri dana liječenja, o tome obavijestite svog liječnika.
Clinical Response at Follow-up (day 12-14), by Analysis population Difference in success rates (%) 
Klinički odgovor na kontrolnom pregledu (12. - 14. dan), prema analiziranoj populaciji Razlika u stopama uspješnosti
This plasma concentration was observed in a child with a secondary infected dermatosis, for which retapamulin is not indicated 
Ta koncentracija u plazmi izmjerena je kod djeteta sa sekundarno inficiranom dermatozom za koju retapamulin nije indiciran.
S. aureus (all) MRSA 
S. aureus (svi) MRSA $
The majority of samples (89%) were below the lower limit of quantitation (0.5 ng/ml). 
Većina je uzoraka (89%) bila ispod donje granice određivanja (0,5 ng/ml).
Lesions of subjects treated with retapamulin healed more quickly by the End of therapy visit (day 7-9), with a reduction in size of the lesions by 77.3% compared to 43.5% for placebo treated subjects. 
Lezije ispitanika koji su liječeni retapamulinom brže su zarastale do posjeta na kraju terapije (7. do 9. dan), sa smanjenjem veličine lezije od 77,3% u usporedbi s 43,5% u ispitanika koji su primali placebo.
Do not stop using this medicine before talking to your doctor or pharmacist. 
Nemojte prestati primjenjivati ovaj lijek prije nego što se savjetujete sa svojim liječnikom ili ljekarnikom.
Therefore the pleuromutilins appear to inhibit bacterial protein synthesis by multiple 
Prema tome, čini se da pleuromutilini inhibiraju bakterijsku sintezu proteina koristeći više mehanizama.
If you accidentally use Altargo inside your nose you could have a nose bleed. 
Ako slučajno nanesete Altargo u nos, možete imati
It is supplied in an aluminium tube with a plastic cap, containing either 5, 10 or 15 grams of ointment, or in an aluminium foil sachet containing 0.5 g of ointment. 
Dolazi u aluminijskoj tubi sa plastičnim čepom koja sadrži 5, 10 ili 15 grama masti, ili u vrećici od aluminijske folije koja sadrži 0,5 g masti.
Data indicate that the binding site involves ribosomal protein L3 and is in the region of the ribosomal P site and peptidyl transferase centre. 
Podaci pokazuju da vezno mjesto uključuje ribosomalni protein L3 te da se nalazi u regiji ribosomalnog P mjesta i centra za peptidil transferazu.
The following convention has been used for the classification of frequency: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1000 to <1/100), rare (>1/10,000 to <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available 
Za klasifikaciju učestalosti koristila su se sljedeća pravila: vrlo često (>1/10), često (>1/100 i <1/10), manje često (>1/1000 i <1/100),
In the Intent to Treat Bacteriological evaluable population, the clinical success rate of retapamulin (76.4%: 139/182) was statistically superior to that of placebo (64.3%; 54/84). 
U bakteriološki ocjenjivoj populaciji koja se namjerava liječiti, stopa kliničke uspješnosti retapamulina (76,4%: 139/182) bila je statistički veća nego kod placeba (64,3%; 54/84).
No studies to evaluate effects of retapamulin on pre-/postnatal development were performed. 
Nisu provedena ispitivanja procjene učinka retapamulina na pre-/postnatalni razvoj.
The in vitro oxidative metabolism of retapamulin in human liver microsomes was primarily mediated by CYP3A4 with minor contributions from CYP2C8 and CYP2D6 (see section 4.5). 
Oksidativni metabolizam retapamulina in vitro na mikrosomima ljudske jetre primarno je posredovan CYP3A4 s manjim udjelom CYP2C8 i CYP2D6 (vidjeti dio 4.5).
Retapamulin is a semi-synthetic derivative of the compound pleuromutilin, which is isolated through fermentation from Clitopilus passeckerianus (formerly Pleurotus passeckerianus). 
Retapamulin je polusintetski derivat spoja pleuromutilina, koji se izolira fermentacijom iz Clitopilus passeckerianus (ranije Pleurotus passeckerianus).
In 14-day (50, 150 or 450 mg/kg) oral toxicity studies in rats there was evidence of adaptive hepatic and thyroid changes. 
U 14. danu (50, 150 ili 450 mg/kg) ispitivanja oralne toksičnosti u štakora postoje dokazi o adaptivnim promjenama jetre i štitnjače.
If the ointment accidentally gets on to these areas, wash the area with water and consult your doctor if you experience discomfort. 
Ako mast slučajno dospije na neko od tih područja, isperite područje vodom i ako osjetite neku tegobu, konzultirajte svog liječnika.
Pharmacotherapeutic group: Antibiotics and chemotherapeutics for dermatological use, Antibiotics for 
Farmakoterapijska skupina: Antibiotici i kemoterapeutici - dermatici, antibiotici za topikalnu primjenu.
Retapamulin ointment should only be used in pregnancy when topical antibacterial therapy is clearly indicated and the use of retapamulin is considered to be preferable to administration of a systemic antibacterial medicinal product. 
U trudnoći se retapamulin mast smije koristiti samo kada je jasno indicirana topikalna antibakterijska terapija i kada se smatra da je korištenje retapamulina bolje nego korištenje sistemskog antibiotika.
Altargo should not be used on children who are less than nine months old. 
Altargo se ne smije koristiti u djece koja su mlađa od devet mjeseci.
However, when adjusted for baseline wound characteristics including pathogen, wound size and severity, the clinical success rate of retapamulin was superior to placebo for the primary efficacy endpoint (p=0.0336). 
Međutim, nakon prilagodbe prema ishodišnim karakteristikama rane uključujući patogen, veličinu rane i težinu infekcije, stopa kliničke uspješnosti retapamulina kao primarne mjere ishoda djelotvornosti (p=0,0336) bila je veća u odnosu na placebo.
There are no data on the effects of retapamulin on human fertility. 
Ne postoje podaci o učincima retapamulina na plodnost ljudi.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not use in the eyes or on mucous membranes. 
DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO Nemojte primjenjivati u oči ili na sluznice.
A thin layer of ointment is usually put on the infected skin twice a day for five days. 
Tanki sloj masti obično se stavlja na inficiranu kožu dva puta dnevno tijekom pet dana.
By virtue of binding to this site, pleuromutilins inhibit peptidyl transfer, partially block P-site interactions, and prevent normal formation of active 50S ribosomal subunits. 
Mogućnošću vezanja za to mjesto, pleutomutilini inhibiraju transfer peptidila, djelomično blokirajući interakcije na P-mjestu i sprječavaju normalno stvaranje aktivne 50S podjedinice ribosoma.
Animal studies have shown reproductive toxicity after oral administration and are insufficient with respect to effects on parturition and fetal/postnatal development (see section 5.3). 
Ispitivanja na životinjama pokazala su reproduktivnu toksičnost nakon peroralne primjene i nisu dostatne za procjenu učinka na porođaj te fetalni/postnatalni razvoj (vidjeti dio 5.3).
Retapamulin selectively inhibits bacterial protein synthesis by interacting at a unique site on the 50S subunit of the bacterial ribosome that is distinct from the binding sites of other non-pleuromutilin antibacterial agents that interact with the ribosome. 
Retapamulin selektivno inhibira sintezu proteina u bakterijama djelovanjem na jedinstveno mjesto na 50S podjedinici bakterijskog ribosoma, koje se razlikuje od veznog mjesta ostalih nepleuromutilinskih antibakterijskih agensa koji reagiraju s ribosomima.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Altargo should be made taking into account the benefit of breast-feeding to the child and the benefit of Altargo therapy to the 
Odluku da li nastaviti/prekinuti dojenje ili nastaviti/prekinuti terapiju lijekom Altargo treba donijeti uzevši u obzir koristi dojenja za dijete i koristi terapije lijekom Altargo za ženu.
One involves mutations in ribosomal protein L3, the second is a non-specific efflux mechanism (ABC transporter vgaAv). 
Jedan uključuje mutaciju ribosomskog proteina L3, drugi je nespecifični mehanizam efluksa (ABC
In human liver microsomes, retapamulin was shown to be a strong inhibitor of CYP3A4. 
Na mikrosomima ljudske jetre se pokazalo da je retapamulin snažni inhibitor CYP3A4.
See also section 4 of this leaflet. 
Pogledajte također dio 4.
This difference was primarily due to the higher success rate observed in retapamulin-treated subjects with infections caused by S. aureus in comparison to placebo treated subjects (see Table below). 
Ova je razlika primarno posljedica veće stope uspješnosti u ispitanika s infekcijama uzrokovanima S. aureus i liječenih retapamulinom u odnosu na one liječene placebom (vidjeti tablicu niže).
There was no evidence of genotoxicity when evaluated in vitro for gene mutation and/or chromosomal effects in the mouse lymphoma cell assay, in cultured human peripheral blood lymphocytes, or when evaluated in vivo for chromosomal effects in a rat micronucleus test. 
Znakovi genotoksičnosti nisu pronađeni pri in vitro procjeni mutacije gena i/ili učinaka na kromosome u testu na stanicama limfoma u miša, na uzgojenim ljudskim limfocitima iz periferne krvi, ili pri in vivo procjenama kromosomskih učinaka koristeći mikronukleus test u štakora.
A multicentre, randomised, double-blind, study compared the efficacy of retapamulin ointment to placebo ointment for the treatment of SIOW. 
Multicentričnim, randomiziranim, dvostruko slijepim ispitivanjem uspoređivana je djelotvornost retapamulin masti u odnosu na placebo mast za liječenje SIOR.
• contact your doctor or pharmacist immediately. 
• odmah se obratite svom liječniku ili ljekarniku.
Any unused medicinal product or waste material should be disposed of in accordance with local 
Neiskorišteni lijek ili otpadni materijal valja zbrinuti sukladno lokalnim propisima.
What you need to know before you use Altargo 
Što morate znati prije nego što počnete primjenjivati Altargo
Retapamulin is not recommended for use in children aged less than 9 months. 
Retapamulin se ne preporučuje za primjenu u djece mlađe od 9 mjeseci.
There was no evidence of impaired fertility in male or female rats at oral doses of 50, 150, or 450 mg/kg/day, resulting in exposure margins of up to 5-times the highest human estimated exposure (topical application to 200 cm2 abraded skin: AUC 238 ng.h/ml). 
Nisu nađeni dokazi oštećenja plodnosti muških ni ženskih štakora pri dozama na usta od 50, 150, ili 450 mg/kg/dan, što je rezultiralo rasponom izloženosti do 5 puta većoj od najveće procijenjene izloženosti za ljude (topikalna primjena na 200 cm2 abradirane kože: AUC 238 ng•h/ml).
For S. aureus isolates with laboratorygenerated mutations in ribosomal protein L3, retapamulin MICs were 0.25-4 µg/ml. 
Kod izolata S. aureus s laboratorijski induciranim mutacijama ribosomalnog proteina L3, vrijednosti MIK za retapamulin su bile 0,25-4 µg/ml.
Due to the very low systemic exposures, tissue distribution of retapamulin has not been investigated in humans. 
S obzirom na vrlo nisku sistemsku izloženost, distribucija retapamulina u tkivima nije ispitivana u ljudi.
* Activity has been satisfactorily demonstrated in clinical studies 
* Zadovoljavajuća aktivnost pokazana je u kliničkim ispitivanjima Klinička djelotvornost i sigurnost
Each gram of ointment contains up to 20 micrograms of butylated hydroxytoluene (E321). 
Jedan gram masti sadrži do 20 mikrograma butilhidroksitoluena (E321).
A thin layer of ointment should be applied to the affected area twice daily for five days. 
Tanak sloj masti potrebno je nanositi na zahvaćeno područje dva puta dnevno tijekom pet dana.
No pharmacokinetic data are available in patients with renal or hepatic impairment. 
Nisu dostupni farmakokinetički podaci za bolesnike s oštećenjem bubrega ili jetre.
Glaxo Operations UK Ltd. (trdg as Glaxo Wellcome Operations) Harmire Road 
Glaxo Operations UK Ltd. (posluje pod imenom Glaxo Wellcome Operations) Harmire Road
The area treated may be covered with sterile bandage or gauze dressing. 
Liječeno područje može se pokriti sterilnim zavojem ili gazom.
Therefore it is not expected that clinically important increases in plasma concentrations of retapamulin will occur in patients aged 2 years and older who are also receiving CYP3A4 inhibitors. 
Prema tome, ne očekuje se klinički značajan porast koncentracije retapamulina u plazmi kod bolesnika u dobi od 2 i više godina koji također primaju inhibitore CYP3A4.
In an embryotoxicity study in rats, developmental toxicity (decreased fetal body weight and delayed skeletal ossification) and maternal toxicity were observed at oral doses of ≥ 150 mg/kg/day 
U ispitivanjima embriotoksičnosti na štakorima, razvojna toksičnost (smanjena tjelesna težina fetusa te zakašnjelo okoštavanje) i toksičnost za majku utvrđene su pri dozama na usta od ≥ 150 mg/kg/dan
Do not use in the eyes or on mucous membranes. 
Nemojte primjenjivati u oči ili na sluznice.
There was no treatment-related effect on embryofetal development. 
Nije bilo učinaka na fetalni razvoj embrija vezanih za terapiju.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
Unutar određene učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Nevertheless, the highest plasma concentrations recorded were low (< 10.5 ng/ml in the absence of ketoconazole and < 17 ng/ml in the presence of ketoconazole. 
Ipak, najviše zabilježene koncentracije u plazmi su bile niske (< 10,5 ng/ml bez ketokonazola i < 17 ng/ml s ketokonazolom).
In vitro, retapamulin was shown to be a P-glycoprotein (Pgp) substrate and inhibitor. 
In vitro, pokazano je da je retapamulin supstrat i inhibitor P-glikoproteina (Pgp).
Any signs or symptoms of overdose, either topically or by accidental ingestion, should be treated 
Sve znakove ili simptome predoziranja, bilo putem kože ili slučajnim uzimanjem na usta, potrebno je liječiti simptomatski.
Your doctor will decide if this 
Liječnik će odlučiti o tome je li ova terapija odgovarajuća za Vas.
Of the samples that had measurable concentrations 90% had retapamulin concentrations less than 2.5 ng/ml. 
Od uzoraka koji su imali mjerljive koncentracije, kod 90% je imalo koncentraciju retapamulina manju od 2,5 ng/ml.
The effect of concurrent application of retapamulin and other topical medicinal products to the same area of skin has not been studied, and is not recommended. 
Učinak istodobne primjene retapamulina i drugih topikalnih lijekova na istom području kože nije ispitan pa se ne preporučuje istodobna primjena.
In the event of a sensitisation or severe local irritation from the use of retapamulin ointment, treatment should be discontinued, the ointment carefully wiped off, and appropriate alternative therapy for the 
U slučaju senzibilizacije ili teške lokalne iritacije zbog primjene retapamulin masti, potrebno je prekinuti liječenje, pažljivo obrisati mast te započeti s alternativnom terapijom infekcije.
In a study conducted in healthy adult subjects, 10 mg/g retapamulin ointment was applied daily to intact and to abraded skin under occlusion for up to 7 days. 
U ispitivanju provedenom na zdravim odraslim ispitanicima, 10 mg/g retapamulin mast je svakodnevno primijenjena na zdravu i na abradiranu kožu pod okluzijom tijekom najviše 7 dana.
Maternal toxicity was demonstrated at dosages of ≥ 7.2 mg/kg/day corresponding to ≥ 8 times the estimated human exposure (see above). 
Toksičnost za majku utvrđena je pri dozama ≥ 7,2 mg/kg/dan koje odgovaraju ≥ 8 puta većoj dozi izloženosti od one procijenjene za ljude (vidjeti gore).
Retapamulin was given as a continuous intravenous infusion to pregnant rabbits from day 7 to day 19 of gestation. 
Retapamulin je davan skotnim kunićima u obliku intravenske infuzije od 7. do 19. dana gestacije.
Butylated hydroxytoluene (E321) 
Bijeli vazelin Butilhidroksitoluen (E321)
Altargo contains butylated hydroxytoluene (E321) It may cause local skin reactions (e.g. contact dermatitis), or irritation of the eyes and mucous 
Altargo sadrži butilhidroksitoluen (E321) On može izazvati lokalne kožne reakcije (npr. kontaktni dermatitis), ili iritaciju očiju i sluznica.
$ In vitro, retapamulin was equally active against methicillin-susceptible and methicillin-resistant strains of S. aureus. 
In vitro, retapamulin je bio jednako učinkovit protiv meticilin-osjetljivih i meticilin-rezistentnih sojeva S. aureus.
Altargo ointment contains an antibiotic called retapamulin, which is used on the skin. 
Što je Altargo i za što se koristi Altargo mast sadrži antibiotik nazvan retapamulin, koji se koristi na koži.
Retapamulin should not be used to treat abscesses. 
Retapamulin se ne smije koristiti za liječenje apscesa.
No treatment-related effects on male or female fertility have been shown in animal studies (see section 5.3). 
U ispitivanjima na životinjama nisu pronađeni učinci povezani s liječenjem na plodnost muških ili ženskih jedinki (vidjeti dio 5.3).
Your doctor will decide if Altargo can be used for a child aged less than 2 years old who is taking other medicines. 
Vaš liječnik će odlučiti može li dijete koje ima manje od 2 godine i uzima druge lijekove koristiti Altargo.
It is unknown whether retapamulin is excreted in human breast milk. 
Nije poznato izlučuje li se retapamulin u majčino mlijeko u ljudi.
Sampling occurred pre-dose for adult subjects on days 3 or 4, and between 0-12 hours after the last application for paediatric subjects on days 3 or 4. 
U odraslih je uzorak uzet prije primjene doze 3. ili 4. dan, a kod pedijatrijskih ispitanika 0-12 sati nakon posljednje primjene 3. ili 4. dan.
$: the response rate for MRSA due to PVL+ MRSA was 8/13 (62%) 
Točan CI se računa korištenjem metode F-distribucije. $: stopa odgovora za MRSA uslijed PVL+ MRSA bila je 8/13 (62%)
Infections that may be treated include impetigo (which causes crusting scabs on infected areas), cuts, grazes and stitched wounds. 
Infekcije koje se mogu liječiti uključuju impetigo (koji na zahvaćenom području uzrokuje kraste koje se gule), porezotine,
However by the Follow-up visit this difference was less pronounced, (88.6% vs, 81% for retapamulin and placebo treated subjects respectively). 
Međutim, do kontrolne posjete razlika je bila manje izražena (88,6% u odnosu na 81% za bolesnike liječene retapamulinom
Very few MRSA were isolated in studies in impetigo and all were clinical successes (100%: 8/8). 
Svega je nekoliko MRSA izolirano pri ispitivanjima impetiga i sve su bile klinički uspješne (100%:
However, since plasma concentrations of retapamulin during topical application have been low (see section 5.2), it is not expected that concurrent systemic administration of CYP3A4 substrates will result in clinically important inhibition of their metabolism by retapamulin. 
Međutim, zbog niskih koncentracija retapamulina u plazmi pri topikalnoj primjeni (vidjeti dio 5.2), ne očekuje se da će istodobna sistemska primjena supstrata CYP3A4 uzrokovati klinički značajnu inhibiciju njihovog metabolizma retapamulinom.
The study failed to meet the primary end point which was the clinical success rate at follow-up (day 12 - 14) for subjects in the Intent to Treat Clinical 
Ispitivanje nije dostiglo primarni ishod koji je bio stopa kliničke uspješnosti (engl. rate) na kontrolnom pregledu (12. - 14. dan) za ispitanike u
0.5 g aluminium foil sachet. 
Vrećica od 0,5 g od aluminijske folije.
No development of resistance was observed during treatment with retapamulin in the clinical study programme and all clinical isolates were inhibited by retapamulin concentrations of <2 µg/ml. 
Tijekom programa kliničkog ispitivanja nije uočen razvoj rezistencije za vrijeme liječenja retapamulinom i svi su klinički izolati bili inhibirani koncentracijama retapamulina od <2 µg/ml.
Contact your doctor or pharmacist for advice. 
Za savjet se obratite svom liječniku ili ljekarniku.
Do not use this medicine after the expiry date which is stated on the carton after ‘EXP'. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju iza ‘Rok valjanosti'.
n/N Success rate 
n/N Stopa uspješnosti
Keep using Altargo for as long as your doctor advises. 
Nastavite koristiti Altargo onoliko dugo koliko Vam to
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infection is questionable. 
U slučaju potrebe, kada je lokalna prevalencija rezistencije takva da je korisnost lijeka za barem neke vrste infekcija upitna, treba potražiti stručan savjet.
Systemic exposure following topical application of retapamulin through intact skin was very low. 
Sistemska izloženost nakon topikalne primjene retapamulina kroz zdravu kožu je bila vrlo niska.
See package leaflet for further information 
Sadržaj pakiranja i dodatne informacije
Therefore caution is advised if retapamulin 10 mg/g ointment is administered to children in this age group who are also receiving CYP3A4 inhibitors, as further increase in systemic exposure to retapamulin may occur upon CYP3A4 inhibition. 
Prema tome, ako se retapamulin 10 mg/g mast primjenjuje djeci te dobne skupine, koja istodobno primaju inhibitore CYP3A4, preporučuje se oprez, s obzirom da je moguć daljnji porast sistemske izloženosti retapamulinu nakon inhibicije CYP3A4.
Check with your doctor or pharmacist if 
Provjerite sa svojim liječnikom ili ljekarnikom ako niste sigurni.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of ointment contains 10 mg retapamulin (1% w/w). 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan gram masti sadrži 10 mg retapamulina (1% m/m).